Chris Rallis - Jul 5, 2024 Form 4 Insider Report for FENNEC PHARMACEUTICALS INC. (FENC)

Role
Director
Signature
/s/ Chris A Rallis
Stock symbol
FENC
Transactions as of
Jul 5, 2024
Transactions value $
-$7,073
Form type
4
Date filed
7/8/2024, 04:05 PM
Previous filing
Apr 15, 2024
Next filing
Aug 19, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FENC Common Shares Options Exercise $5K +1.79K +3.91% $2.79* 47.6K Jul 5, 2024 Direct F1
transaction FENC Common Shares Sale -$7.07K -1.17K -2.46% $6.03 46.5K Jul 5, 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FENC Common Shares Options Exercise -$5K -1.79K -0.99% $2.79* 180K Jul 5, 2024 Options 1.79K $2.79 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Shares acquired through the exercise of an option pursuant to a 10b5-1 plan adopted on August 17, 2023.
F2 Shares sold to satisfy tax obligation on option exercise.
F3 Represents options exercised pursuant to a 10b5-1 program adopted August 17, 2023.